Sunil Reddy, MD
Medical Oncology · Stanford, CANPI 1578645057
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Immunocore Limited at 25.3% of the total. 2025 is the largest year on record at $1,785, 2.1 times the $836 reported in 2019. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 83 payments — averaging $59.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$1K
- Varian Medical Systems, Inc.$960
- Pfizer$500
- E.r. Squibb & Sons, L.L.C.$454
- EMD Serono, Inc.$448
- Galvanize Therapeutics, Inc$221
- plus $1K from 9 others
Across 212 payments — averaging $6267.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Trisalus Life Sciences, Inc.$852K
- E.r. Squibb & Sons, L.L.C.$196K
- Novartis$135K
- Genentech, Inc.$92K
- Incyte Corporation$51K
- Merck$2K
What the payments were for
- Consulting fees$96019%
- Speaking & faculty fees$2084%
- Travel & lodging$1,08422%
- Food & beverage$2,69854%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 4 | $1,254 |
| Varian Medical Systems, Inc. | 1 | $960 |
| Pfizer | 22 | $500 |
| E.r. Squibb & Sons, L.L.C. | 6 | $454 |
| EMD Serono, Inc. | 33 | $448 |
| Galvanize Therapeutics, Inc | 1 | $221 |
| Taiho Oncology, Inc. | 3 | $207 |
| Array Biopharma Inc | 3 | $192 |
| Novocure Inc. | 1 | $147 |
| AstraZeneca | 3 | $141 |
| Delcath Systems | 1 | $140 |
| Regeneron | 1 | $116 |
| Trisalus Life Sciences, Inc. | 1 | $101 |
| Bristol Myers Squibb | 2 | $51 |
| Eisai Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$1,155
- ALIYA SYSTEM$221
- BRAFTOVI$160
- MEKTOVI$160
- Oncology$147
- Hepzato Kit$140
- LIBTAYO$116
- TRINAV INFUSION SYSTEM$101
How this compares
$4,957 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 18 | $200 |
| Oxycodone Hcl | 12 | $100 |
| Prednisone | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.